Features Partner Sites Information LinkXpress
Sign In
Demo Company

New Single Step ELISA Kits Available for Multiple Analytes

By BiotechDaily International staff writers
Posted on 11 Sep 2013
Print article
A new line of ELISA kits with a universal simplified protocol is now available for biotech and life science researchers.

The Abcam plc. (Cambridge, United Kingdom) line of SimpleStep ELISA kits currently comprise kits for the detection of more than 35 molecules ranging from interleukins and interferons to tumor markers.

Abcam states that the new single wash, colorimetric sandwich ELISA kits have a greatly simplified protocol when compared to standard multistep ELISAs, providing significant timesaving and ease of use. This is accomplished by employing a labeled capture and detection antibody which, "immunocapture" the specific analyte from the sample solution. This entire complex (capture antibody/protein/detection antibody) is in turn immobilized in the well of the microtiter plate via the immunoaffinity of an anti-tag antibody coated in the microplate well.

The unified operational protocol calls for a single one-hour incubation at room temperature and a single wash step. Furthermore, the new SimpleStep platform requires no specific training or new instrumentation.

James Murray, general manager of Abcam, said, “Abcam is continually in touch with researchers to anticipate the latest research trends and developments, so that we can continue to meet their needs worldwide. We are excited to see how SimpleStep ELISA kits will help to increase the pace of scientific discoveries.”

Related Links:
Abcam plc.

Print article



view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

How Blocking TROY Signaling Slows Brain Cancer Growth

Cancer researchers have found how the low molecular weight drug propentofylline (PPF) slows the growth of the aggressive brain tumor glioblastoma multiforme (GBM). This form of brain cancer is the most... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.